SI-BONE, Inc. (NASDAQ:SIBN) is reporting third quarter financial results on Monday 2nd November 2020, after market close.
According to analysts surveyed by Thomson Reuters, SIBN is expected to report 3Q20 loss of $ 0.39 per share from revenue of $ 16.42 million.
For the full year, analysts anticipate top line of $ 68.48 million, while looking forward to loss of $ 1.6 per share bottom line.
The Company Outlook
Revenue for 3Q20 are expected in a range of $ 20.10 million ~ $ 20.40 million
Full Year 2020 topline are forecasted in a range of$ 73.00 million ~ $ 74.00 million
Click Here For More Historical Outlooks Of SI-BONE, Inc.
Previous Quarter Performance
SI-BONE, Inc. communicated loss for the second quarter of $ 0.44 per share, from the revenue of $ 14.05 million. According to street consensus, SIBN was expected to report 2Q20 loss of $ 0.64 per share from revenue of $ 8.29 million. The bottom line results beat street analysts by $ 0.2 or 31.25 percent, at the same time, top line results outshined analysts by $ 5.76 million or 69.48 percent.
Stock Performance
On Friday, shares of SI-BONE, Inc. has traded high as $ 21.40 and has cracked $ 20.40 on the downward trend, reaching $ 20.97 with volume of 224.40 thousand shares.
According to the previous trading day, closing price of $ 20.97, representing a 192.22 % increase from the 52 week low of $ 7.20 and a 20.33 % decrease over the 52 week high of $ 26.41.
The company has a market capital of $ 667.82 million and is part of the Healthcare sector and Medical Devices industry.
Recent Analyst recommendations
- On 30th September 2020, maintained by JMP Securities at Market Outperform rating, with $ 27.00 target price.
Conference Call
SI-BONE, Inc. will be hosting a conference call at 4:30 PM eastern time on 2nd November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website si-bone.com
SI-BONE, Inc., a medical device company, develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. It offers iFuse, an implant system to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain. The company was founded in 2008 and is headquartered in Santa Clara, California.
